Phase 3 PhALLON trial reveals high rates of MRD negativity at any time and prolonged PFS with ponatinib in patients with newly diagnosed Ph+ ALL

First-line lorlatinib continues to show PFS benefit over crizotinib in patients with advanced ALK+ NSCLC: 5-year follow-up of the CROWN study

Local long-term study reveals high chronic health and mortality risks for nasopharyngeal cancer survivors

Observational study highlights clinical characteristics and treatment patterns of patients with high-risk prostate cancer in Asia-Pacific

Improved outcomes with FLOT perioperative chemotherapy vs. CROSS neoadjuvant chemoradiation for esophageal cancer: The ESOPEC Trial

Liver transplantation + chemotherapy improves survival rates for patients with unresectable colorectal liver metastases

EFS improvements for early-stage TNBC patients with carboplatin addition to standard therapy